Noninvasive Cardiac Imaging in Patients With Hypertrophic Cardiomyopathy  by Nagueh, Sherif F. & Mahmarian, John J.
N
P
S
H
H
i
0
f
a
p
p
t
w
H
E
E
i
p
a
d
v
m
p
m
o
L
c
u
v
t
c
t
t
m
c
M
m
a
m
M
a
Journal of the American College of Cardiology Vol. 48, No. 12, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Poninvasive Cardiac Imaging in
atients With Hypertrophic Cardiomyopathy
herif F. Nagueh, MD, FACC, John J. Mahmarian, MD, FACC
ouston, Texas
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and the
most common cause of cardiac death in young athletes in the U.S. Noninvasive imaging plays an
important role in detecting the disease, understanding its pathophysiology, and selecting as well
as guiding appropriate therapy. In this review, we discuss the existing methodology with emphasis
on current and emerging clinical applications in patients with HCM. (J Am Coll Cardiol 2006;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.06548:2410–22) © 2006 by the American College of Cardiology Foundation
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sypertrophic cardiomyopathy (HCM) is the most common
nherited cardiomyopathy, with an estimated prevalence of
.2% (1). It is caused by100 mutations in 11 genes coding
or sarcomeric proteins (2) and is a common cause of death
mong athletes (1). Noninvasive cardiac imaging techniques
lay a pivotal role in detecting the disease, understanding its
athophysiology and selecting and guiding appropriate
herapy. In this review, we discuss the existing methodology
ith emphasis on current and emerging applications in
CM patients.
CHOCARDIOGRAPHY
chocardiography has been used since its early days to gain
nsight into this complex disease, because it provides a
ractical and comprehensive assessment of cardiac structure
nd function (Table 1). In addition to left ventricular (LV)
imensions and volumes, the pattern and extent of left
entricular hypertrophy (LVH) can be determined. Asym-
etric LVH (Fig. 1) is most commonly observed (95%),
articularly with upper septal hypertrophy (3). However,
id ventricular, apical, or posterolateral hypertrophy also
ccur. In addition, up to 5% of patients have concentric
VH. During acquisition and analysis, one has to exercise
aution to avoid oblique transection of the septum by the
ltrasound beam and to exclude myocardium on the right
entricular (RV) side of the septum when measuring septal
hickness. The identification of the apical variant can be
hallenging but is significantly enhanced by high frequency
ransducers and intravenous contrast agents.
Quantification of LV mass poses problems with conven-
ional methods, given the variable wall thickness and di-
ensions throughout the LV. Reasonable alternatives in-
lude semiquantitative scores such as the Wigle (3) and the
aron and Spirito score (4). The latter reports the sum of
aximal wall thickness taken from septal, posterior, lateral,
nd anterior myocardial areas in the short axis views at
itral and papillary muscle levels.
From the Department of Cardiology, The Methodist DeBakey Heart Center, The
ethodist Hospital, Houston, Texas.l
Manuscript received February 2, 2006; revised manuscript received June 28, 2006,
ccepted July 30, 2006.More recently, real time 3-dimensional echocardiography
as been applied to determine LV mass, but there is a
aucity of data about its accuracy in HCM. Maximal wall
hickness is a simple and important measurement that
hould be reported, because it can predict sudden cardiac
eath in this population (5).
ifferential diagnosis. Before establishing the diagnosis of
CM, other reasons for LVH such as hypertension and
ortic stenosis should be excluded, although at times they
oexist with HCM. The patients for whom the diagnosis of
CM is easiest to establish are those who have positive
amily history or harbor a known mutation with advanced
symmetric LVH, despite a mild degree of aortic stenosis or
ell controlled hypertension. By contrast, the diagnosis of
CM is difficult to ascertain in patients with mild concen-
ric LVH and hypertension or aortic stenosis. Recently,
ore severely reduced systolic compression (by strain
oppler echocardiography) along with asymmetric LVH
eadily identified biopsy-proven HCM patients from those
ith hypertension (6).
Up to 30% of HCM patients have systolic anterior
otion (SAM) of the mitral valve, leading to left ventricular
utflow tract (LVOT) obstruction. However, SAM is not
athognomonic of HCM. Systolic anterior motion has been
bserved in elderly women with hypertension, sigmoid
eptum, and a hyperdynamic state due to anemia and/or
ypovolemia (7). It is also noted after mitral valve repair
ith an annular ring and anterior displacement of the
nterior mitral valve leaflet (8). Other causes of dynamic
bstruction are listed in Table 2.
The differential diagnosis includes cardiac amyloidosis,
umors, adherent thrombi, and Fabry disease. The latter is
n X-linked recessive metabolic defect that frequently re-
ults in cardiac hypertrophy and should be considered in
en with unexplained LVH. The diagnosis can be reliably
ade in men by measuring the serum level of the lysosomal
nzyme alpha-galactosidase and noting the binary appear-
nce of LV endocardial border by echocardiography (9).
his diagnosis should be entertained, given the presence of
pecific enzyme replacement therapy that results in regres-
ion of LVH and improvement of cardiac function. Table 2
ists other metabolic defects.
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December 19, 2006:2410–22 Noninvasive Imaging in HCMetection of HCM in athletes. Diagnosis of HCM in
thletes is important, given the high propensity to sudden
ardiac death in HCM patients engaging in competitive
ports. The diagnosis can be particularly challenging in
thletes with an advanced degree of physiologic LVH.
elpful clues include the presence of wall thickness 12
m (11 mm in women) in the presence of a non-dilated
V (10) in HCM, because HCM patients usually have
ormal or reduced LV dimensions and no cavity dilatation
55 mm is common in athletes), except with disease
rogression and systolic dysfunction. Hypertrophic cardio-
yopathy patients have abnormal myocardial function as
etected by tissue Doppler (TD) imaging, including mitral
nnulus velocities and myocardial early diastolic velocity
Ea) gradient or strain rate (11). In equivocal cases, it is
easonable to recommend stopping exercise with repeat
maging later, when one would expect regression of physi-
logic but not pathologic LVH.
ssessment of systolic function. This is performed with
hortening fraction and/or ejection fraction (EF). Most
CM patients have hyperdynamic EF, whereas a small
ubset might develop LV enlargement along with depressed
able 1. Echocardiographic Evaluation of Cardiac Structure and
unction in Patients With Hypertrophic Cardiomyopathy
V dimensions and volumes
attern of LV hypertrophy (asymmetric, concentric, or apical)
eptal, posterior, and maximum wall thickness
VEF
V relaxation and filling pressures (using Ea by TD and E/Ea ratio)
ulmonary artery systolic pressure (using tricuspid regurgitation jet)
A maximum volume
V size, function, and whether RV hypertrophy is noted
resence and location of dynamic obstruction and whether chordal or
valvular SAM is noted
agnitude of outflow tract gradient at rest and Valsalva
resence and magnitude of dynamic obstruction in the RV outflow tract
resence and severity of mitral regurgitation
he presence of co-existing pathology, such as aortic, pericardial disease,
and so on
 mitral E; Ea  early diastolic velocity; EF  ejection fraction; LA  left atrial;
Abbreviations and Acronyms
Aa  late diastolic velocity
AV  atrioventricular
Ea  early diastolic velocity
EF  ejection fraction
HCM  hypertrophic cardiomyopathy
LA  left atrium/atrial
LV  left ventricle/ventricular
LVH  left ventricular hypertrophy
LVOT  left ventricular outflow tract
MR  mitral regurgitation
RV  right ventricle/ventricular
SAM  systolic anterior motion
SPECT  single-photon emission computed tomography
TD  tissue Dopplert
V  left ventricular; RV  right ventricular; SAM  systolic anterior motion;
D  tissue Doppler.F (1). The presence of LV enlargement and depressed EF
ersus normal EF is important for proper selection of
edical therapy, because patients with depressed EF should
eceive angiotensin-converting enzyme inhibitors and car-
iac glycosides, which are avoided in patients with LVOT
bstruction.
In HCM a normal EF does not exclude contractile
ysfunction, which can be detected by more sensitive
igure 1. (A) Asymmetric septal hypertrophy; (B) concentric hypertrophy;
C) apical hypertrophy.echniques such as myocardial systolic velocities, strain rate,
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Noninvasive Imaging in HCM December 19, 2006:2410–22nd strain (6,11). Notwithstanding, at this time, it is
easonable to report LVEF until the incremental and
rognostic value of the new methods are determined.
igure 2. (Upper left) Mitral left ventricular (LV) inflow; (upper right) pul
nnulus; (lower right) tricuspid regurgitation (TR) jet by continuous w
ystolic/diastolic (S/D) velocity (and time velocity integral) ratio1 in the p
s increased both in amplitude and duration, indicating increased LV end di
able 2. Differential Diagnosis of Hypertrophic
ardiomyopathy
Differential Diagnosis of LVH
thlete’s heart
ypertension
alvular aortic stenosis
ub-valvular fixed obstruction
abry disease
lycogen storage disorders
riedrich ataxia
itochondrial myopathy
ardiac amyloidosis
eptal tumors
dherent thrombi
Differential Diagnosis of Dynamic Outflow Tract Obstruction
lderly women with hypertension, sigmoid septum, and
hyperdynamic EF
fter mitral valve repair
fter acute MI with apical dysfunction and hyperdynamic basal function
assive posterior mitral annulus calcification
nomalous papillary muscle
fter aortic valve replacement with LVH and hyperdynamic EF
VH left ventricular hypertrophy; MImyocardial infarction; other abbreviations
s in Table 1.Aa) velocity ratio is1, indicating abnormal LV relaxation. The E/Ea ratio is in
.8 m/s, indicating an RV and pulmonary artery (PA) systolic pressure of at leassessment of diastolic function. The accuracy of mitral
nd pulmonary venous flow in evaluating LV diastolic
unction was explored in a number of cross sectional studies.
oth LV and left atrial (LA) filling abnormalities have been
oted, but no close correlation was observed between
oppler filling patterns, extent of LVH, and invasive
ndexes of diastolic function (12), with the exception of the
trial flow signal recorded from the pulmonary veins, which
as a significant correlation with LV end diastolic pressure
13). In contrast, TD imaging in combination with trans-
itral inflow can provide reasonably accurate predictions of
lling pressures (13). Tissue Doppler recording of the mitral
nnulus motion is obtained by placing a 5-mm sample
olume at the septal and lateral sites of the annulus, with
djustment of scale, gains, and filters to allow for a clear
ignal with minimal background noise. It is possible to
easure the absolute value of the early (Ea) and late (Aa)
iastolic velocities as well as Ea/Aa and mitral E to annular
a ratios (Fig. 2). Importantly, E/Ea ratio detects changes
n filling pressures after alcohol-induced septal ablation
14,15) and cardiac surgery (15) and predicts exercise
olerance in adults (16) and children (17) with HCM. In
ddition, septal Ea is an independent predictor of death and
entricular dysrhythmia in children with HCM (17).
Left atrial volume reflects the LA hemodynamic burden
rom LV diastolic dysfunction, mitral regurgitation (MR),
ry venous flow; (lower left) tissue Doppler velocities at lateral side of mitral
(CW) Doppler. Mitral inflow is pseudonormal (E/A ratio of 1), and
nary veins. However, atrial reversal (Ar) velocity in pulmonary venous flow
c pressure. The early diastolic (Ea) velocity is reduced and Ea/ late diastolicmona
ave
ulmo
astoli
creased to 12.5, indicating increased LV pre-A pressure. Peak TR velocity
st 31 mm Hg.
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December 19, 2006:2410–22 Noninvasive Imaging in HCMnd atrial myopathy. A number of studies have now re-
orted a significant association between LA dimensions and
ubsequent development of atrial fibrillation as well as
dverse outcomes after myectomy (18).
ynamic obstruction. This dynamic abnormality has cap-
ured the attention of cardiologists and surgeons over the
ears and remains so at this time. Obstruction can occur at
ultiple levels in the same patient and is variable with time
1), being dependent on intravascular blood volume, after-
oad, and cardiac contractility. It is important to perform
areful mapping by pulse wave Doppler to determine the
ite of obstruction. Continuous wave (CW) Doppler is used
o determine peak LVOT gradient with caution exercised to
xclude the MR jet.
A number of theories have been examined to understand
he mechanisms of LVOT obstruction, and the 2 most
iable are the Venturi (3) and drag forces. The Venturi
heory proposes that the earliest event is an increased
jection velocity, leading to an increase in kinetic energy.
iven the principle of conservation of energy, the increase
n kinetic energy is accompanied by a decrease in potential
nergy and local pressure leading to the anterior motion of
he mitral valve. This in turn leads to a gap between the
nterior and posterior mitral leaflets through which MR
ccurs (i.e., “eject, obstruct, leak” sequence) (3). In contrast,
he theory implicating drag forces (19) looks at anterior
ovement of the mitral valve because of drag forces, which
ct on the posterior surface of the valve and are proportional
o the surface area of the leaflets exposed to these forces and
ystolic flow velocity. This mechanism is supported by the
resence of SAM at a time when the LVOT velocity is not
ncreased (20). Irrespective of the underlying mechanism(s),
VOT obstruction is associated with worse clinical out-
omes, including death and heart failure (21).
It is also important to look for dynamic obstruction in the
V outflow tract, which can occur in younger subjects.
rovocable obstruction. A number of methods can pro-
oke obstruction in the echocardiography laboratory, in-
luding Valsalva maneuver, amyl nitrite, exercise, and do-
utamine. It is relatively easy to acquire data during the
train phase of Valsalva in most patients, but when the
radient is 30 mm Hg, particularly in highly symptomatic
atients, it is reasonable to proceed to other methods of
rovoking obstruction.
For those able to exercise, exercise Doppler should be used
1), because exercise is the modality that most closely simulates
hysiologic stress. Additional data such as exercise duration,
lood pressure with exercise, and peak oxygen consumption
ay be obtained during the same test. Although supine bike
xercise is more conducive to acquiring multiple hemodynamic
ata sets, this position increases venous return and might
ecrease the likelihood and extent of LVOT obstruction.
ccordingly, upright exercise, which has the greatest resem-
lance to daily physiologic activities, should be used.
For patients unable or unwilling to exercise, medical
rovocation is a viable alternative. Isoproternol, because of pts positive inotropic properties, has been used for decades in
he catheterization laboratory, providing the rationale and
recedent for dobutamine injection in the echocardiography
aboratory. The use of dobutamine is not advocated for
ubjects with LVH due to hypertension and not HCM; nor
s it advocated for HCM patients who are asymptomatic
ith mild symptoms or able and willing to exercise. The
nfusion protocol starts with a drip rate of 5 g/kg/min up
o 20 g/kg/min. Importantly, treating provocable obstruc-
ion has resulted in significant clinical, exercise, and hemo-
ynamic improvement (22).
R. Mitral regurgitation can occur in HCM patients
ecause of rheumatic heart disease or myxomatous degen-
ration. In patients with dynamic obstruction, MR jet is
irected posterolaterally. The direction of the MR jet is an
mportant clue for the underlying mechanism (23), because
n anteriorly/medially directed jet is not related to dynamic
bstruction but is due to a primary leaflet pathology (Fig. 3).
chocardiographic studies (24) have drawn attention to the
educed mobility and length of the posterior mitral leaflet
eading to a shorter coaptation length and therefore a longer
ree segment of the anterior leaflet that is amenable to drag
orces. Mitral regurgitation related to dynamic obstruction
s improved by septal reduction therapy (25,26).
chocardiography to guide treatment in HCM. Symp-
omatic patients with LVOT obstruction are treated with
egative inotropic drugs (beta-blockers, verapamil, dilti-
zem, and disopyramide) as the first line of therapy. These
rugs decrease LVOT gradient by reducing acceleration rate of
V systolic flow and prolonging acceleration time relative to
jection time, thereby reducing the time available for the build
p of the dynamic gradient (27). A successful response to
edical therapy results in an improvement of cardiac symp-
oms and a reduction in LVOT gradient that can be assessed
y Doppler echocardiography. In addition, beta-blockers,
erapamil, and diltiazem prolong the diastolic filling time
nd reduce the likelihood of developing ischemia through
heir favorable effect on ischemia/demand balance.
acemaker therapy. When medical therapy fails or cannot
e tolerated, other options are considered, including pacing.
here is seldom a need for transthoracic imaging during
mplantation of a pacemaker. However, if there are doubts
bout whether the RV lead is positioned in the apex or there
re concerns about cardiac perforation, transthoracic imag-
ng should be performed.
As for hemodynamic effects, initial observational studies
ere encouraging, but randomized controlled studies
howed a highly variable and modest benefit from pacing
1). Unlike patients with congestive heart failure and de-
ressed EF where an improvement of LV dyssynchrony is
ought with biventricular pacing, RV pacing in patients with
bstructive HCM is used to induce further dyssynchrony to
ecrease LVOT gradient (28), as recently demonstrated by
D. Because HCM patients have normal atrioventricular
AV) conduction, a short AV delay is needed for ventricular
acing. However, this approach can result in abbreviated
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Noninvasive Imaging in HCM December 19, 2006:2410–22V diastolic filling, reduction in stroke volume, and increase
n filling pressures. It is therefore imperative to identify the
ongest AV delay that leads to adequate filling yet results in
omplete ventricular pre-excitation. To achieve this objec-
ive, Doppler echocardiography is applied to determine the
ffects of different AV delays on LV diastolic filling time.
chocardiography can monitor the effects of pacing on
VOT gradient and filling pressures.
chocardiographic evaluation for septal reduction
herapy. Septal reduction therapy is feasible with intra-
oronary ethanol and surgical myectomy. For both proce-
ures, dynamic obstruction at rest (30 to 50 mm Hg) or
rovocation (60 mm Hg) should be present as well as a
eptal thickness of 1.6 cm.
Before septal reduction, it is important to identify the site
f obstruction (i.e., SAM vs. mid or distal obstruction).
his distinction is essential, because reduction of septal base
hickness will not result in an improvement of distal
bstruction. It is also important to identify co-existing
alvular disease that warrants surgery, for example sub-
igure 3. (Left) Flail segment of posterior mitral leaflet. (Right) Color Doppl
igure 4. (Left) Transesophageal echocardiography of left ventricular out
ignal of abnormal flow. Note the early peaking with a gradient of almost 100 m
ynamic obstruction. AV  aortic valve; LA  left atrium; LV  left ventriclealvular fixed stenosis (Fig. 4), anomalous insertion of
apillary muscle, or a flail valve. It can be challenging to
ssess the severity of aortic stenosis in patients with obstruc-
ive HCM, and it is reasonable to proceed, if needed, to
ransesophageal echocardiography to measure the aortic
alve area by planimetry in short axis views.
When septal reduction therapy cannot be performed
ecause of inadequate septal thickness, plication of anterior
itral leaflet or mitral valve replacement can be considered.
lcohol septal reduction. During alcohol septal reduction
herapy, procedural guidance with myocardial contrast
chocardiography is important (Fig. 5) (29). This results in
significantly shorter procedure time and lower likelihood
f heart block (30). In addition, it is possible to identify the
yocardial territory of septal perforator branches that arise
rom vessels other than the left anterior descending coronary
rtery. Contrast opacification of other LV/RV segments or
apillary muscle precludes the injection of ethanol, which
ould result in infarction outside the culprit septal segments
ut not septal reduction. The risk area by myocardial
eccentric mitral regurgitation jet directed antero-medially. LA left atrium.
tract showing sub-valvular membrane (arrow). (Right) Continuous waveflow
m Hg and the presence of aortic regurgitation. Both are unexpected with
.
c
s
r
m
r
o
w
d
r
n
l
i
r
v
d
A
r
(
s
m
p
m
f
p
l
w
w
S
p
r
t
r
a
i
t
m
F
D septal
F
b
r
2415JACC Vol. 48, No. 12, 2006 Nagueh and Mahmarian
December 19, 2006:2410–22 Noninvasive Imaging in HCMontrast echocardiography relates significantly to the perfu-
ion defect size by single-photon emission computed tomog-
aphy (SPECT), peak creatine kinase leak (29), and develop-
ent of heart block and ventricular dysrhythmia (31).
The reduction of LVOT gradient in the acute phase is
elated to the decrease in systolic thickening and excursion
f septal base due to necrosis/ischemia-stunning (Fig. 6) as
ell as global decrease in LV systolic function, which can be
etected by invasive measurements and peak acceleration
ate of LV ejection (25). An acute improvement is usually
oted in the severity of MR without significant change in
eaflet mobility (25). Later on, LVOT widening, reduction
n drag forces, and decrease in peak LV ejection acceleration
ate account for the reduction in LVOT obstruction (25).
After alcohol septal reduction therapy, LV end-diastolic
olume increases and septal and maximal wall thickness
ecrease as well as EF, albeit still in the normal range (32).
s for LV diastolic function, the time constant of LV
elaxation shortens (14) and filling pressures are reduced
igure 5. (Left) Apical long-axis view after opacification of septal base wi
oppler showing the site of flow acceleration in relation to the opacified
igure 6. Septal and lateral base function by Doppler strain–time curves, a
ase of the septum is dysfunctional. The arrow points to post-systolic compress
elated to abnormal loading conditions and possibly ischemia.14,15,30). Interestingly, despite septal infarction, LV dys-
ynchrony improves and contributes to the acute improve-
ent in LV relaxation (33). Left ventricular stiffness im-
roves as well (14,34) and is related to the decrease in LV
ass/volume ratio (32), total collagen and collagen I iso-
orm (34), and improvement in LV relaxation. The im-
rovement in LV diastolic function and the severity of MR
ead to a decrease in LA volumes, ejection force, and stroke
ork, which nevertheless remain significantly increased
hen compared with a normal group (35).
urgery. During surgery, transesophageal echocardiogra-
hy is needed (36) to determine the adequacy of septal
esection, because inadequate septal resection is an impor-
ant cause of residual obstruction. Additional reasons for
epeat surgery include mid-ventricular obstruction and
nomalous papillary muscle insertion (37). Both can be
dentified by echocardiography and surgical inspection of
he LVOT. In contrast to alcohol septal reduction therapy,
ost of the reduction in LVOT gradient after surgery
iographic contrast in the course of alcohol septal ablation. (Right) Color
base.
cohol injection. Systolic compression is present in the lateral wall, but theth radfter al
ion, which is not uncommon in hypertrophic cardiomyopathy and seems
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Noninvasive Imaging in HCM December 19, 2006:2410–22ccurs acutely owing to widening of the LVOT, which is
aintained at follow-up. Transesophageal echocardiogra-
hy is also important in determining the adequacy of mitral
alve repair in cases with MR due to primary leaflet
athology or with additional surgical procedures, such as
alve plication/extension. In most patients, postoperative
omplications (when suspected), such as pericardial effusion,
ortic regurgitation, and septal rupture, can be readily
iagnosed by transthoracic imaging.
Surgical myectomy results in increase in LV volumes,
ecrease in LV systolic function (26), and reduction in LV
ass and filling pressures (15).
creening and pre-clinical diagnosis of HCM. Echocar-
iography is the most practical technique at the present time
or HCM screening. It is considered in first degree relatives
nd potentially in other family members of the index cases.
iven the adolescent growth spurt, repeat imaging at yearly
ntervals is reasonable during this time period (38). Repeat
maging is also considered for adults at longer time intervals
f 5 years (38) because of the possibility of later develop-
ent of LVH (39). All myocardial segments—and not only
he interventricular septum—should be carefully examined
or screening purposes. In a recent study where genotyping
as the gold standard, the Spirito-Maron hypertrophy score
as highly specific with a better sensitivity than maximal
all thickness (40).
Studies from transgenic animal models have noted the
resence of abnormal myocardial function (41) at a time
receding the development of LVH. These observations
ave led to the investigation of TD imaging in the pre-
linical diagnosis of HCM in individuals carrying sarco-
eric protein mutations encoding HCM. Four reports have
igure 7. (A) Parasternal long- and short-axis views and tissue Doppler (
ubject carrying a known mutation for hypertrophic cardiomyopathy. Le
elocities are reduced for age. (B) After 2 years, asymmetric septal hypertrophy
ate diastolic velocity; LA  left atrium; LV  left ventricle; RV  right ventrrovided encouraging results (42–45), with an additional
tudy (39) showing subsequent LVH in such subjects (Fig. 7).
n addition, this methodology proved accurate in the identifi-
ation of patients with Fabry disease without LVH (46).
However, additional data from a larger number of sub-
ects is needed to determine TD velocity values that provide
he highest diagnostic accuracy with narrow confidence
ntervals. Additional limitations to this approach include the
ower specificity in older individuals or those with coexisting
isease, such as hypertension and coronary artery disease,
hich can result in abnormal myocardial function. Further-
ore, it is difficult to interpret Doppler data and provide
ounsel to subjects who carry the mutation but who still have
ormal velocity values. Given the variable penetrance, these
ubjects might never develop HCM including abnormal myo-
ardial function. Alternatively, it is possible that the abnormal-
ty in cardiac function is present but at a mild degree that is not
menable to diagnosis by TD (role of strain imaging as more
ensitive marker of myocardial disease remains to be estab-
ished). Therefore, repeat imaging is reasonable, possibly at
early intervals, in an attempt to detect myocardial dysfunction
nd/or LVH if and when they develop.
UCLEAR IMAGING
n the past 2 decades, gated blood pool radionuclide
ngiography has provided helpful insights into the measure-
ent of LV volumes, EF, and filling rates in HCM
atients. Verapamil has been shown to increase the peak
lling rate and to shorten the time to peak filling rate in
CM patients (47). Because LV filling rates and time
ntervals are affected not only by LV relaxation but also
velocities at lateral and septal side of mitral annulus, from a 20-year-old
tricular hypertrophy is absent, but systolic (Sa) and early diastolic (Ea)TD)
ft vendeveloped and TD annular velocities remain reduced. AO  aorta; Aa 
icle.
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December 19, 2006:2410–22 Noninvasive Imaging in HCMlling pressures, it is possible to observe pseudonormal
lling rates when filling pressures are increased. At the
resent time, echocardiography is applied to assess diastolic
unction because it allows beat to beat measurement of
lling patterns and the acquisition of less load-dependent
ndexes of LV relaxation.
PECT myocardial perfusion imaging. Patients with
CM might have epicardial coronary artery disease, and many
CM patients with chest pain undergo stress perfusion
maging to detect ischemia. Treadmill, bicycle exercise, atrial
acing, dipyridamole, and adenosine were examined in this
opulation. Defects, both reversible and fixed, were noted from
0% to 100% of the patients imaged (see Table 3 from Keng
t al. [48] for a summary). Most defects involve the septum but
an occur in other walls. Although the general principles of
PECT interpretation apply to HCM patients, cardiologists
hould be cautious of “hot spots.” These have increased count
ctivity and are most frequently noted in the septum in patients
ith asymmetric LVH. The increased count activity might be
elated to LVH and/or increased regional blood flow. Irrespec-
ive of the etiology of “hot spots,” if the tomographic slices are
ormalized to this area of increased count activity, regions
djacent to and distinct from the “hot spot” will appear
elatively less intense, thereby creating spurious perfusion
efects (Fig. 8). Inaccurate image interpretation can be avoided
y paying attention to the location and type of perfusion
efects. The lateral wall is most frequently involved, and
erfusion defects are usually fixed. Furthermore, on gated
igure 8. Single-photon emission computed tomography perfusion imagin
s the count activity (hot spot) in the septum relative to lateral wall. The compu
nd apical regions upon normalization to the septum. HLA  horizontal long axisPECT images, normal regional function will be noted despite
he apparently reduced perfusion.
Abnormal myocardial perfusion in HCM patients, de-
pite normal coronary angiography, has been linked to
udden cardiac death (49). More recently, worse prognosis
as noted with microvascular dysfunction as determined by
yocardial blood flow and coronary flow reserve measured
y 13N labeled ammonia (50). Aside from perfusion defects,
dditional abnormalities have been reported, including in-
reased washout rates of Tc-99m tetrofosmin, which is
ositively correlated with New York Heart Association
unctional class and wall thickness (51).
PECT monitoring of results of non-medical therapy.
verall the published literature reports on few HCM
atients who had nuclear imaging studies after non-medical
herapy. In 20 patients who underwent surgical myectomy
r mitral valve replacement, an improvement of myocardial
erfusion was noted in most patients (52). However, 4
eveloped new fixed defects after surgery along with a large
ecrement in EF (26 15%) that was statistically significant
hen compared with the remaining patients (3  14%, p
0.01).
In the largest report with gated SPECT after alcohol septal
eduction therapy in 30 patients, only fixed septal perfusion
efects were present after alcohol injection involving basal
100% of patients) and mid septum (38% of patients). In
ddition, significant reductions in lung to heart and in septal to
ateral wall count ratios were noted (48). These observations
m a hypertrophic cardiomyopathy patient. Septal thickness is increased asg fro
ter analysis software registered a fixed perfusion defect (scar) in the lateral
; PDS  perfusion defect size; SA  short axis; VLA  vertical long axis.
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Noninvasive Imaging in HCM December 19, 2006:2410–22re due to the reduction of LV filling pressures and septal
hickness after alcohol-induced infarction.
maging of metabolism and myocardial receptors in HCM.
number of interesting observations were made with
ardiac metabolic and neurotransmission imaging. BMIPP
iodine-123-beta-methyl-iodophenylpentadecanoic acid, a
arker of fatty acid metabolism) imaging was investigated
n Japanese patients with HCM. BMIPP uptake was
ecreased, whereas its washout was increased in HCM (53),
ith regional BMIPP dynamics related to regional function
nd perfusion.
Intriguing observations were noted with iodine-123 la-
eled MIBG (metaiodobenzylguanidine), which tracks the
resynaptic uptake and storage of neurotransmitters. In one
tudy, HCM patients with ventricular tachycardia had a
ignificantly higher MIBG global washout rate, which was
he most powerful predictor of ventricular tachycardia on
ultiple regression analysis (54). Interestingly, a progressive
ecrease in MIBG uptake and increase in its washout rate
re noted in HCM patients, as LV size increases and EF
ecreases (55).
Other studies (56,57) have explored changes in beta-
drenergic receptor density, with the radioactive tracers
ED (11C-hydroxyephedrine) and 11C-CGP-12177 (po-
ent hydrophilic beta-blocker, with little cellular uptake).
hese studies demonstrated the presence of reduced beta-
drenergic receptor density with reduced norepinephrine
euptake by presynaptic terminals. The reduction in beta-
drenergic receptor density seems to be particularly promi-
ent in patients with heart failure (58).
Collectively, the aforementioned findings suggest that
utonomic dysfunction might play a role in sudden death,
isease progression, and the development of heart failure in
CM. However, additional studies are needed in a larger
umber of patients to corroborate these observations.
AGNETIC RESONANCE IMAGING (MRI)
ardiac morphology. Recent studies have shown that
RI can be applied to measure LV dimensions, volumes,
nd EF with high reproducibility (59), including in patients
ith LVH. In HCM, MRI plays a major role in identifying
he pattern and extent of hypertrophy (Fig. 9), which can be
ore extensive than appreciated by echocardiography, par-
icularly in the anterolateral free wall (60). This is also true
ith apical LVH (61). Furthermore, it is possible to identify
arly disease when hypertrophy is limited to the apical
egion of the lateral wall (62). Follow-up by MRI has shown
hat these cases progress to circumferential hypertrophy (62)
nd the “spade”-like configuration. Therefore, MRI or
ontrast echocardiography is essential when evaluating pa-
ients with anterolateral T-wave abnormalities and no ob-
ious underlying etiology. In addition, given its accuracy,
his technique is useful for familial screening and genetic
inkage studies. In summary, cardiac MRI is considered a Hlass I indication for patients with apical HCM and a class
I indication for other phenotypic variants of HCM (59).
egional function. Systolic wall thickening and circum-
erential strain can be measured with the tagging sequence
here a grid of dark lines is laid across the image (Fig. 9).
ith contraction, the grid is deformed and can be used to
erive myocardial strain. It can also detect LV dyssynchrony
y measuring the time interval to maximal wall thickening
n different regions (63).
Magnetic resonance imaging studies have shown re-
uced circumferential shortening in hypertrophied seg-
ents with an inverse relation to local thickness and with
ost shortening occurring in early systole (64,65). Lon-
itudinal shortening is likewise reduced in the basal
eptum (65). On a global basis, the number of hypoki-
etic segments is a strong independent predictor of LV
ass, confirming the association of LVH with myocar-
ial dysfunction (66).
V hemodynamic condition. Cine MRI is useful for
dentifying the presence of MR and its severity (59) as well
s SAM (67,68) (see online Appendix for supplemental
ideos). It is possible to quantify MR volume as the
ifference between LV and RV stroke volumes or by
ubtracting aortic flow (by velocity mapping) from LV
troke volume. In patients with SAM, a signal void area is
resent in the LVOT during systole. This signal reaches its
aximal intensity in early systole in patients with severe
bstruction (68).
The LV diastolic function can be examined with phase-
ontrast magnetic resonance to determine mitral E and
eptal Ea velocities. The E/Ea ratio by magnetic resonance
eems to have a good correlation with invasively measured
ean wedge pressure (69). Although these initial results are
romising, additional studies are needed, including those in
atients with HCM. There are also concerns with the MRI
echnique in unstable patients or those with contraindica-
ions to MRI and the long time needed for offline analysis.
or the aforementioned reasons, Doppler echocardiography
s the method of choice for hemodynamic assessment in
igure 9. End-diastolic (left) and end-systolic (right) frames with the grid
aid across the image. Notice the increased anteroseptal thickness and the
educed stripe deformation in that area.CM patients.
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December 19, 2006:2410–22 Noninvasive Imaging in HCMissue characterization. Abnormal areas of hyperen-
ancement by gadolinium can be noted in some HCM
atients. There are different patterns for these areas. In the
enign pattern, hyperenhancing areas are present at the
unction between the RV and LV. Another pattern is
haracterized by a patchy distribution in other regions, the
xtent of which is positively correlated with regional wall
hickness and inversely with systolic thickening (70). Fur-
hermore, its overall extent is inversely related to EF and is
igher in patients with LV dilation and 2 risk factors of
udden cardiac death (71). On histopathology (Fig. 10),
hese areas correspond to regions of increased collagen but
ot disarray (72). This is an important area for future
esearch, because MRI might play a critical role in
dentifying HCM patients who should be considered for
rimary prevention by automatic implantable defibrilla-
ors (AICD) devices. Abnormal gadolinium hyperen-
ancement has also been noted in the basal infero-lateral
all in patients with Fabry disease (73).
ssessment of results of septal reduction therapy. There
re few MRI studies that examined the changes in cardiac
tructure and function after septal reduction procedures. In 1
eries with 37 patients, cine MRI was successfully used before
urgical myectomy to grade the severity of SAM and LVOT
bstruction with the aorta/LVOT signal ratio. In the 4 patients
ho were studied after surgery, SAM grade and the aorta/
VOT signal ratio decreased significantly (67).
More recently, MRI was used to study patients who
nderwent ethanol septal reduction therapy. These carefully
igure 10. (A) In vivo end diastolic images, (B) in vivo gadolinium-enhan
ith sirius red for collagen. Areas of gadolinium enhancement correspond
s marked by the arrow. Reproduced with permission from Moon et al. (7erformed sequential studies identified several changes.
C
pith gradient echo sequences in 10 patients, a continuous
nd non-linear improvement of the outflow tract area was
oted during a 12-month period of follow-up, which
orrelated well with symptomatic improvement (74). The
ize of septal infarct averaged 20  9 g (10  5% of the
V). Infarct size by MRI related well with peak creatine
inase leak (75), similar to myocardial contrast echocardi-
graphy (29). The LV remodeling was observed early and
ages, (C) corresponding sections from explanted heart, and (D) staining
stained pale myocardium and red-stained collagen. A representative area
able 3. Comparison of Existing and Potential Roles of
chocardiography, Nuclear Imaging, and MRI in the
valuation of Patients With HCM
Echocardiography
Nuclear
Imaging
Cardiac
MRI
V dimensions and
volumes
 / 
V wall thickness, mass  / 
V EF   
egional function   
V filling pressures   
A pressure: rest and
exercise
  
A volume and function   
ynamic obstruction   
itral regurgitation   
schemia/CFR   
ardiac metabolism   
eurotransmission   
onitoring of therapy   
issue characterization  ? 
re-clinical diagnosis  ? ced imFR  coronary flow reserve; HCM  hypertrophic cardiomyopathy; PA 
ulmonary artery; other abbreviations as in Tables 1 and 2.
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Noninvasive Imaging in HCM December 19, 2006:2410–22rogressed at 6 months of follow-up. Similar to that
bserved in echocardiographic studies (32), regression of
VH was observed at remote sites not involved with
nfarction and the change in LV mass was significantly
elated to infarct location and the reduction of LVOT
radient (76).
reclinical diagnosis. A number of studies using 31P
uclear magnetic resonance spectroscopy reported on the
resence of abnormal myocardial metabolism in HCM
atients (77). In an attempt to identify patients at a
reclinical stage, Crilley et al. (78) used this methodology to
etermine the cardiac phosphocreatine (PCr)/adenosine
riphosphate (ATP) ratio in 31 patients. The PCr/ATP
atio was reduced in the HCM group by 30% relative to the
ontrol group, including 7 subjects without LVH, suggest-
ng that abnormal cardiac energetics might play a role in
evelopment of the disease.
However, with respect to pre-clinical diagnosis, the
verlap of values with the control group is an important
imitation. It remains to be seen whether this strategy can be
sed for predicting disease progression, because PCr/ATP
atio might decrease further with the development of
ypertrophy and heart failure.
ONCLUSIONS
n summary, imaging can provide important information
hat is needed for the appropriate evaluation of HCM
atients. Each of the imaging modalities discussed in the
revious text has its advantages and drawbacks and, depend-
ng on the clinical situation, one might need information
rom 1 or more of these techniques (Table 3). In addition to
linical risk factors, imaging studies can play a critical role in
isk stratification for sudden cardiac death (Table 4). How-
ver, their full potential remains to be realized.
cknowledgment
he authors thank Ms. Maria Frias for her editorial
able 4. Application of Cardiac Imaging for the Risk
tratification of Sudden Cardiac Death in Patients With HCM
chocardiography
LV maximal wall thickness (30 mm)
LV dilatation and depressed EF
Reduced septal Ea in children
LVOT gradient at rest 30 mm Hg (better predictor for overall
mortality)
uclear imaging
Perfusion defects
Reduced coronary flow reserve
Increased MIBG washout rate
ardiac MRI
LV maximal wall thickness (30 mm)
LV dilatation and depressed EF
Late enhancing areas with late gadolinium-enhanced images
VOT  left ventricular outflow tract; MIBG  metaiodobenzylguanidine; other
bbreviations as in Tables 1 and 2.ssistance.
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PPENDIX
o view videos referenced in the text, please see the online
ersion of this article.
